Skip to main content

Outcomes of liver transplantation using Hepatitis B core-positive liver grafts: Implications for prophylaxis

Abstract

The number of patients listed for liver transplantation has outpaced the number of transplants that can be performed. This disparity between transplant candidates and the availability of donor grafts has led to an increase in mortality for patients waiting for liver transplantation. One strategy used to increase the donor pool has been the utilization of expanded donor grafts, such as those from donors with hepatitis B core antibody (anti-HBc). However, use of anti-HBc-positive grafts can potentially place the recipient at risk of de novo post-transplant hepatitis B virus (HBV) infection. The spectrum of liver disease from de novo hepatitis B ranges from mild hepatitis to graft loss. Fortunately, the risk of de novo HBV infection can be decreased with administration of oral nucleosides or nucleotides and hepatitis B immunoglobulin to the recipient. This review focuses on the epidemiology, natural history, and prophylactic strategies to reduce the risk of de novo hepatitis B in liver transplant recipients who receive anti-HBc-positive grafts.

This is a preview of subscription content, access via your institution.

References and Recommended Reading

  1. Chung RT, Feng S, Delmonico FL: Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001, 1:185–191. Important paper addressing current state of evaluation, treatment, and surveillance of the allograft recipients exposed to hepatitis B.

    PubMed  CAS  Google Scholar 

  2. Dodson SF, Issa S, Araya V, et al.: Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997, 64:1582–1584.

    PubMed  Article  CAS  Google Scholar 

  3. Douglas DD, Rakela J, Taswell HF, et al.: Transmission of hepatitis B virus (HBV) infection from orthotopic donor livers [abstract]. Hepatology 1992, 16:49A.

    Article  Google Scholar 

  4. Chazouilleres O, Mamish D, Kim M, et al.: "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994, 343:142–146.

    PubMed  Article  CAS  Google Scholar 

  5. Wachs ME, Amend WJ, Ascher NL, et al.: The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995, 59:230–234.

    PubMed  Article  CAS  Google Scholar 

  6. Uemoto S, Sugiyama K, Marusawa H, et al.: Transmission of hepatitis B virus from hepatitis B core antibodypositive donors in living related liver transplants. Transplantation 1998, 65:494–499.

    PubMed  Article  CAS  Google Scholar 

  7. Prieto M, Gomez MD, Berenguer M, et al.: De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7:51–58.

    PubMed  Article  CAS  Google Scholar 

  8. Douglas DD, Rakela J, Wright TL, et al.: The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997, 3:105–111.

    PubMed  Article  CAS  Google Scholar 

  9. Manzarbeitia C, Reich DJ, Ortiz JA, et al.: Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002, 8:556–561. Demonstrated safety of using hepatitis B core antibody (HBcAb)-positive liver grafts.

    PubMed  Article  Google Scholar 

  10. Roque-Afonso AM, Feray C, Samuel D, et al.: Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002, 50:95–99.

    PubMed  Article  CAS  Google Scholar 

  11. Yu AS, Vierling JM, Colquhoun SD, et al.: Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001, 7:513–517.

    PubMed  Article  CAS  Google Scholar 

  12. Chen YS, Wang CC, de Villa VH, et al.: Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002, 16:405–409.

    PubMed  Article  Google Scholar 

  13. Lee KH, Wai CT, Lim SG, et al.: Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001, 7:469–470.

    PubMed  CAS  Article  Google Scholar 

  14. Berner J, Kadian M, Post J, et al.: Prophylactic recombinant hepatitis B vaccine in patients undergoing orthotopic liver transplantation. Transplant Proc 1993, 25:1751–1752.

    PubMed  CAS  Google Scholar 

  15. Segovia R, Sanchez-Fueyo A, Rimola A, et al.: Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001, 7:106–112.

    PubMed  Article  CAS  Google Scholar 

  16. Crippin J, Foster B, Carlen S, et al.: Retransplantation in hepatitis B: a multicenter experience. Transplantation 1994, 57:823–826.

    PubMed  Article  CAS  Google Scholar 

  17. Tipples GA, Ma MM, Fischer KP, et al.: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24:714–717.

    PubMed  CAS  Google Scholar 

  18. O’Grady JG, Smith HM, Davies SE, et al.: Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14:104–111.

    PubMed  Article  CAS  Google Scholar 

  19. Terrault NA, Zhou S, Combs C, et al.: Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996, 24:1327–1333.

    PubMed  Article  CAS  Google Scholar 

  20. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ: Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978, 298:1379–1383.

    PubMed  CAS  Article  Google Scholar 

  21. de Villa VH, Chen YS, Chen CL: Hepatitis B core antibodypositive grafts: recipient’s risk. Transplantation 2003, 75:S49-S53.

    PubMed  Article  Google Scholar 

  22. Douglas DD, Rakela J, Taswell HF, et al.: Hepatitis B virus replication patterns after orthotopic liver transplantation: de novo versus recurrent infection. Transplant Proc 1993, 25:1755–1757.

    PubMed  CAS  Google Scholar 

  23. Aldersley MA, Eglin RE, O’Grady JG: Liver transplantation and de novo hepatitis B infection. Lancet 1994, 343:677.

    PubMed  Article  CAS  Google Scholar 

  24. Dodson SF, Bonham CA, Geller DA, et al.: Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999, 68:1058–1061.

    PubMed  Article  CAS  Google Scholar 

  25. Bartholomew MM, Jansen RW, Jeffers LJ, et al.: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997, 349:20–22.

    PubMed  Article  CAS  Google Scholar 

  26. Schiff ER, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419–1427.

    PubMed  CAS  Google Scholar 

  27. Burton JR Jr, Shaw-Stiffel TA: Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003, 9:837–842.

    PubMed  Article  Google Scholar 

  28. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al.: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14–18.

    PubMed  CAS  Google Scholar 

  29. Chien RN, Liaw YF, Atkins M: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999, 30:770–774.

    PubMed  Article  CAS  Google Scholar 

  30. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, et al.: Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis 1996, 28:17–20.

    PubMed  CAS  Google Scholar 

  31. Jilg W, Hottentrager B, Weinberger K, et al.: Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001, 63:96–102.

    PubMed  Article  CAS  Google Scholar 

  32. Saab S, Chang AJ, Comulada S, et al.: Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003, 9:1053–1061. Demonstrates that HBc-positive grafts can be used in non-hepatitis B-infected individuals.

    PubMed  Article  Google Scholar 

  33. Bárcena R, Domínguez-Antonaya, López-Sanromán A, et al.: Lamivudine therapy of hepatitis B virus-related liver disease: cirrhosis, post-transplantation recurrence, and de novo infection. Transplant Proc 1999, 31:2457–2458.

    PubMed  Article  Google Scholar 

  34. Joya-Vazquez PP, Dodson FS, Dvorchik I, et al.: Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002, 73:1598–1602.

    PubMed  Article  Google Scholar 

  35. Anselmo DM, Ghobrial RM, Jung LC, et al.: New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002, 235:611–619.

    PubMed  Article  Google Scholar 

  36. Katsurada A, Marusawa H, Uemoto S, et al.: Circulating antibody to hepatitis B core antigen does not always reflect the latent hepatitis B virus infection in the liver tissue. Hepatol Res 2003, 25:105–114.

    PubMed  Article  CAS  Google Scholar 

  37. Lo CM, Fan ST, Liu CL, et al.: Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003, 9:827–832.

    PubMed  Article  Google Scholar 

  38. Rokuhara A, Tanaka A, Yagi S, et al.: De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 2000, 62:471–478.

    PubMed  Article  CAS  Google Scholar 

  39. Fontana RJ, Merion RM: Are we ready for marginal hepatitis B core antibody-positive living liver donors? Liver Transpl 2003, 9:833–836. Excellent review on clinical implications of using HBcAb-positive living liver donors.

    PubMed  Article  Google Scholar 

  40. Gallegos-Orozco J, Vargas H, Rakela J: Virologically compromised donor grafts in liver transplantation. Hepatology 2004, 41:512–521.

    Article  Google Scholar 

  41. Vargas HE, Dodson FS, Rakela J: A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl 2002, 8:2–9.

    PubMed  Article  Google Scholar 

  42. Castells L, Esteban R: Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001, 13:359–361.

    PubMed  Article  CAS  Google Scholar 

  43. Domínguez M, Bárcena R, García M, et al.: Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000, 6:440–442.

    PubMed  Article  Google Scholar 

  44. Perrillo RP, Wright T, Rakela J, et al.: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 3:424–432.

    Article  Google Scholar 

  45. Xiong X, Flores C, Yang H, et al.: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669–1673.

    PubMed  Article  CAS  Google Scholar 

  46. Holt D, Thomas R, Van Thiel D, Brems JJ: Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002, 137:572–575.

    PubMed  Article  CAS  Google Scholar 

  47. Loss GE, Mason AL, Blazek J, et al.: Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 2001, 156:55–58.

    Article  Google Scholar 

  48. Fabrega E, Garcia-Suarez C, Guerra A, et al.: Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003, 9:916–920.

    PubMed  Article  Google Scholar 

  49. Nery JR, Nery-Avila C, Reddy KR, et al.: Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003, 75:1179–1186.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sammy Saab MD, MPH.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nieto, J.M., Saab, S. Outcomes of liver transplantation using Hepatitis B core-positive liver grafts: Implications for prophylaxis. Curr hepatitis rep 5, 33–39 (2006). https://doi.org/10.1007/s11901-006-0021-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-006-0021-0

Keywords

  • Liver Transplantation
  • Lamivudine
  • Liver Transplant Recipient
  • Liver Graft
  • Adefovir Dipivoxil